Stay updated with breaking news from Phil Low. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
West Lafayette IN (SPX) Jun 27, 2023 - Adranos Inc., a Purdue-originated company that grew from a doctoral project into an impactful company, has been acquired by a major Costa Mesa, California-based defense products company, Anduril Ind
Low says the gift is enough to fund what would normally amount to 40 years of grant funding for cancer research. However, he adds the funding likely will not last
Cytalux (pafolacianince), a drug that binds to ovarian cancer tissue and glows when exposed to fluorescent light, has been approved by the U.S. Food and Drug Administration (FDA) to help surgeons detect ovarian tumors during surgical procedures in patients.
E-Mail IMAGE: The image shows fractured femurs at three weeks post-fracture. Yellow and orange colors indicate higher density bone than purple and blue and the green arrows point towards the fracture site.... view more Credit: Novosteo Inc. Novosteo Inc., a preclinical-stage biotechnology startup focused on the development of bone-targeted therapeutics, announced Thursday (February 4) the closing of a $5.5 million in Series A financing to advance its development of the first-ever targeted bone anabolic agent NOV004. The compound has shown promise in live animals in the acceleratio...
Date Time Share Bone treatment startup raises $5.5 M in Series A financing, names pharmaceutical leader William Boyle as CEO The image above shows fractured femurs at three weeks post-fracture. Yellow and orange colors indicate higher density bone than purple and blue and the green arrows point towards the fracture site. The “targeted” bone received Novosteo’s injectable-targeted drug, whereas the control bone did not receive drug, representing current therapies. Comparing the two bones, the additional bone growth caused by Novosteo’s drug could help people with fractures return to ...